New York Patent of the Month – February 2023

The COVID-19 pandemic has wreaked havoc on the world, causing significant loss of life and economic devastation. With over 178 million confirmed cases and 3.8 million deaths worldwide, the need for effective treatment options is more urgent than ever before. In light of this situation, Curemark, LLC, a clinical-stage biopharmaceutical company, is  working towards developing a potential treatment option for COVID-19.

Curemark is a pharmaceutical company that develops innovative treatments for a range of medical conditions. While their lead product candidate, CM-AT, is a patented enzyme-based therapy designed to address the underlying biochemistry of autism, the company directs their expertise to a number of therapies for neurological conditions and unmet medical needs. Curemark has recently patented a novel treatment pathway, leveraging the use of enzyme-based therapies to treat COVID-19 treatment, leveraging its expertise in enzyme-based therapies.

The current COVID-19 prevention and treatment guidelines are unsustainable in terms of human loss, economic impact, and the burden on the healthcare system. The long-term symptoms associated with the virus are also alarming, with the potential to damage the lungs, heart, and brain, leading to long-term health problems. There is a pressing need for a treatment option that can not only help with immediate recovery but also prevent long-term damage caused by the virus.

Curemark’s COVID-19 treatment candidate, CM-101, is a small molecule drug that has been shown to significantly reduce the production of cytokines, which are responsible for the immune system’s overreaction to the virus. This overreaction can lead to severe symptoms and damage to multiple organs, making CM-101 a promising treatment option.

The drug is currently in phase III clinical trials, and the results have been encouraging. In preclinical studies, CM-101 reduced lung inflammation and improved lung function in animal models infected with SARS-CoV-2. Additionally, the drug has been shown to reduce viral replication, leading to a faster recovery from COVID-19.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts